Karman Holdings Inc.
KRMN
$35.28
+2.59%
Karman Holdings Inc. designs, tests, manufactures, and sells mission-critical systems for missile, defense, and space programs, organized into three solution families: Payload Protection and Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company serves three core end markets — Hypersonics & Strategic Missile Defense, Missile & Integrated Defense Systems, and Space & Launch — positioning it as a specialized, sole-source-like supplier to Department of Defense and space-sector prime contractors rather than a broad-line defense prime. The current investor narrative has shifted violently from a post-IPO defense/space growth darling to a battleground stock: a short-seller report questioning its acquisition strategy and valuation has driven shares sharply lower, even as the company reported record Q1 2026 results with 51% revenue growth, a roughly $1 billion backlog, and raised guidance. Bulls point to accelerating top-line growth, expanding gross margins, and structural demand from hypersonics and space launch bottlenecks; bears focus on the serial-M&A capital allocation, negative free cash flow, and a valuation that remains extreme on trailing earnings despite the drawdown.…
KRMN
Karman Holdings Inc.
$35.28
Related headlines
Investment Opinion: Should I buy KRMN Today?
The synthesized recommendation is Hold, with a speculative bias. The core thesis is that Karman's accelerating revenue growth (51% YoY) and expanding gross margins (42.24%) are compelling, but the extreme valuation (PS 20.53x, EV/EBITDA 85.42x), negative free cash flow (-$31.00 million TTM), and high leverage (debt-to-equity 1.53) create an unfavorable risk/reward at the current price. The analyst consensus is 'strong_buy' with an average target of $92.67, implying +162.7% upside, but these targets appear stale given the recent 43% one-month decline and may not yet reflect the short-seller report's impact.
Supporting evidence for a Hold includes: (1) revenue growth of 51.02% YoY in Q1 2026, far exceeding the sector's typical mid-single-digit growth; (2) gross margin expansion from 39.40% to 42.24% YoY, showing pricing power and operating leverage; (3) a ~$1 billion backlog and raised guidance, indicating strong demand; and (4) a current ratio of 3.29 and $73.80 million in cash, providing near-term liquidity. However, these positives are offset by a trailing PE of 562.85x, negative TTM FCF of -$31.00 million, and interest coverage of only 1.70x, which leave little margin for error.
The biggest risks that could invalidate the thesis are: (1) a continued decline in organic growth or failure to integrate acquisitions, which would undermine the growth narrative; (2) a breach of debt covenants due to high leverage and low interest coverage; and (3) a further de-rating if the short-seller report's allegations gain traction. The rating would upgrade to Buy if free cash flow turns positive and the stock stabilizes above $45, or downgrade to Sell if revenue growth decelerates below 20% or if the stock breaks below the 52-week low of $33.99. Relative to its history and peers, the stock is overvalued on most metrics, though the recent decline has compressed multiples from their post-IPO peaks.
Sign up to view all
KRMN 12-Month Price Forecast
Karman presents a high-risk, high-reward scenario. The company's accelerating revenue growth and expanding gross margins are impressive, but the extreme valuation, negative free cash flow, and high leverage create significant downside risk. The recent short-seller report has introduced substantial uncertainty, and the stock's severe technical downtrend suggests the market is pricing in a bearish outcome. I would upgrade to bullish if the company demonstrates positive free cash flow and organic growth above 30% for two consecutive quarters, and downgrade to bearish if free cash flow remains negative or if the stock breaks below $33.99.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Karman Holdings Inc.'s 12-month outlook, with a consensus price target around $92.67 and implied upside of +162.7% versus the current price.
Average Target
$92.67
0 analysts
Implied Upside
+162.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$78 - $135
Analyst target range
Nine analysts cover Karman, and the consensus recommendation is "strong_buy" with a recommendation mean of 1.3 (where 1.0 is a strong buy and 5.0 is a sell). The average target price is $92.67, which implies +162.7% upside from the current price of $35.28 — an extraordinarily wide gap that reflects either a massive disconnect between analyst models and market pricing or stale targets that have not been updated following the recent short-seller report and sharp decline. The consensus clearly leans bullish, but the magnitude of the implied upside should be treated with skepticism given that the stock has fallen 43% in the past month alone and analysts may be lagging the news flow.
The target range spans from a low of $78.00 to a high of $135.00 — a spread of $57.00, or 73% of the low target — signaling very high uncertainty and low conviction even among bulls. The high target of $135.00 implies roughly 283% upside and would require a full recovery to near the 52-week high of $118.38, assuming multiple expansion, successful integration of acquisitions, and resolution of short-seller concerns. The low target of $78.00 still implies +121% upside, suggesting even the most conservative analyst sees substantial value — but the fact that no analyst target is below $78 while the stock trades at $35.28 indicates either a severe mispricing or that targets are stale. Institutional ratings show a mix of reiterations: Citigroup (Buy), KeyBanc (Overweight), Piper Sandler (Overweight), Evercore ISI (Outperform), and Needham (Buy) on the bullish side, versus BWS Financial (Sell) as the lone bear; notably, all recent actions are reiterations rather than upgrades or downgrades, suggesting analysts are in a holding pattern awaiting the company's response to the short-seller report and clearer visibility on organic growth and cash flow generation.
Bulls vs Bears: KRMN Investment Factors
The bear case currently has stronger evidence due to the severe technical breakdown, negative free cash flow, and extreme valuation multiples that leave no room for error. However, the bull case is not without merit: revenue growth is accelerating at 51%, gross margins are expanding, and the company has a ~$1 billion backlog with raised guidance. The single most important tension is whether the 51% revenue growth is sustainable and increasingly organic, or whether it is largely acquisition-driven and masking underlying cash flow problems. If Karman can demonstrate organic growth and positive free cash flow in coming quarters, the stock could re-rate sharply; if not, the downtrend may continue toward the 52-week low.
Bullish
- Revenue growth accelerating to 51%: Q1 2026 revenue of $151.21 million grew 51.02% year-over-year, up from roughly 35% growth in mid-2025, with sequential increases every quarter from $115.10 million in Q2 2025 to $151.21 million in Q1 2026. This acceleration, combined with a ~$1 billion backlog and raised guidance, signals robust demand for hypersonics, missile defense, and space systems.
- Profitability inflection with margin expansion: Karman swung from a -$4.80 million net loss in Q1 2025 to +$7.79 million net income in Q1 2026, while gross margin expanded from 39.40% to 42.24% over the same period. Operating margin of 14.19% and EBITDA margin of 25.07% demonstrate improving operating leverage despite heavy interest expense.
- Extreme analyst upside and strong buy consensus: Nine analysts rate the stock a consensus 'strong_buy' with a mean recommendation of 1.3, and the average target price of $92.67 implies +162.7% upside from the current $35.28. Even the lowest target of $78.00 implies +121% upside, suggesting a severe disconnect between analyst models and market pricing.
- Structural defense demand and space bottleneck: Karman supplies mission-critical systems for hypersonics, strategic missile defense, and space launch — areas with rising geopolitical tensions (Iran, per recent news) and a severe launch capacity shortage that creates pricing power. The company's sole-source-like positioning with DoD prime contractors provides revenue visibility.
Bearish
- Extreme valuation on every metric: Trailing PE is 562.85x, PS is 20.53x, EV/EBITDA is 85.42x, and PB is 25.30x — multiples typically reserved for high-growth software, not defense hardware. Even after a 44.70% one-year decline, the stock trades at a steep premium to aerospace & defense peers that typically command 2–4x sales.
- Negative free cash flow and high leverage: Despite positive net income, Q1 2026 operating cash flow was only $0.21 million and free cash flow was -$7.17 million, with TTM FCF at -$31.00 million. Debt-to-equity of 1.53 and interest coverage of just 1.70x leave little cushion, and the company funded $210.15 million of acquisitions through external financing.
- Short-seller report and acquisition concerns: A short-seller report questioning Karman's acquisition strategy and valuation has driven shares sharply lower, with the stock down 43.01% in the past month alone. The report raises valid questions about how much of the 51% revenue growth is organic versus acquired, especially after $210.15 million of Q1 2026 acquisition spending.
- Severe technical downtrend and relative weakness: The stock is down 64.71% over six months and 44.70% over one year, massively underperforming the S&P 500's +16.22% gain (relative strength -60.92%). At $35.28, it sits just 3.8% above its 52-week low of $33.99, with a max drawdown of -70.17% and accelerating downside momentum (-43.01% in one month).
KRMN Technical Analysis
Karman is in a severe, sustained downtrend, with the 1-year price change at -44.70% and the 6-month change at -64.71%, a decline that dwarfs the S&P 500's +16.22% gain over the same 1-year window (relative strength of -60.92%). At $35.28, the stock sits just 3.8% above its 52-week low of $33.99 and 70.2% below its 52-week high of $118.38 — effectively trading at the very bottom of its 52-week range (roughly 4% of range). This positioning is characteristic of a falling-knife setup rather than a value opportunity: the stock has lost more than two-thirds of its peak value, and the maximum drawdown of -70.17% confirms that buyers at any point in the last year are deeply underwater, creating persistent overhead supply.
Short-term momentum is decisively negative and accelerating to the downside: the 1-month change is -43.01% versus the 3-month change of -26.24%, meaning the pace of decline has steepened dramatically in the most recent month. This is a clear divergence from the already-weak longer-term trend — the stock is not merely drifting lower but is in a capitulation phase, with the 1-month relative strength of -41.95% against a roughly flat SPY (-1.06%) showing the selloff is company-specific rather than market-driven. The short ratio of 5.72 days-to-cover indicates meaningful short interest that could fuel sharp squeezes on any positive catalyst, but it also reflects entrenched bearish conviction. Volume of 3.69 million shares on the latest session, with the stock up 2.59% on the day, hints at tentative dip-buying interest near the lows, though a single up-day does not reverse a downtrend of this magnitude.
Key technical levels are starkly defined: support sits at the 52-week low of $33.99, just $1.29 below the current $35.28 price, and a decisive breakdown below that level would open the door to price discovery to the downside with no historical reference points. Resistance is layered far overhead, with the 52-week high at $118.38 representing a 236% advance required to reclaim prior highs; intermediate resistance would likely form around the $45–$50 zone where the stock consolidated in July and August 2026. The stock's volatility profile is extreme — a -70.17% max drawdown and a 1-month move of -43% imply a beta well above 1 relative to the market, meaning position sizing should be conservative and stop-loss discipline is critical; a beta of 1.5 would imply 50% more volatility than SPY, but Karman's realized volatility is clearly far higher than that benchmark.
Beta
—
—
Max Drawdown
-70.2%
Largest decline past year
52-Week Range
$34-$118
Price range past year
Annual Return
-44.7%
Cumulative gain past year
| Period | KRMN Return | S&P 500 |
|---|---|---|
| 1m | -43.0% | -1.6% |
| 3m | -26.2% | +1.3% |
| 6m | -64.7% | +13.9% |
| 1y | -44.7% | +16.3% |
| ytd | -54.1% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KRMN Fundamental Analysis
Karman's revenue trajectory is genuinely strong and accelerating: Q1 2026 (period ended 2026-03-31) revenue was $151.21 million, up 51.02% year-over-year from $100.12 million in Q1 2025. The multi-quarter trend shows consistent sequential growth — $115.10 million in Q2 2025, $121.79 million in Q3 2025, $134.49 million in Q4 2025, and $151.21 million in Q1 2026 — with the YoY growth rate inflecting from roughly 35% in mid-2025 to over 51% in the most recent quarter. This acceleration, combined with a reported ~$1 billion backlog and raised guidance, suggests the demand environment for hypersonics, missile defense, and space systems is robust; however, the growth is partly inorganic, as the company deployed $210.15 million on acquisitions in Q1 2026 alone, meaning investors must scrutinize how much of the 51% growth is organic versus acquired.
Profitability is positive but thin at the bottom line: Q1 2026 net income was $7.79 million on $151.21 million of revenue, a net margin of just 5.15%, while gross margin was a healthy 42.24% and operating margin was 14.19%. The gap between 42% gross margin and 5% net margin is explained by heavy interest expense ($12.65 million in Q1 2026) and other expenses ($13.78 million), which consumed nearly all of the $21.45 million in operating income. Encouragingly, gross margin has expanded from 39.40% in Q1 2025 to 42.24% in Q1 2026, and the company swung from a -$4.80 million net loss in Q1 2025 to +$7.79 million net income in Q1 2026 — a clear profitability inflection. Still, the 5% net margin is well below what mature aerospace and defense suppliers typically earn (often 8–12%), reflecting the company's subscale size, acquisition-related amortization, and leveraged balance sheet.
Balance sheet and cash flow metrics reveal the central risk: despite positive net income, Karman generated only $0.21 million in operating cash flow in Q1 2026 and burned $7.17 million in free cash flow, with trailing-twelve-month FCF at -$31.00 million. The debt-to-equity ratio of 1.53 and total debt-to-capitalization of 68.12% indicate a heavily leveraged capital structure, and interest coverage of just 1.70x leaves little cushion — a single bad quarter could pressure covenant compliance. Liquidity is a relative bright spot, with a current ratio of 3.29 and quick ratio of 3.38, and cash of $73.80 million at quarter-end, but the company funded its $210.15 million acquisition spree and $262.03 million of debt repayment through $257.16 million of net financing inflows, meaning it remains dependent on external capital markets. ROE of 4.54% and ROA of 5.14% are modest and below the cost of capital, underscoring that the company is not yet generating sufficient returns to self-fund its growth ambitions.
Quarterly Revenue
$151210000.0B
2026-03
Revenue YoY Growth
+51.0%
YoY Comparison
Gross Margin
42.2%
Latest Quarter
Free Cash Flow
$-30995000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KRMN Overvalued?
Because Karman is profitable on a trailing basis (net income of $7.79 million in Q1 2026, positive TTM earnings), the PE ratio is the appropriate primary metric — but it is nearly meaningless at current levels: the trailing PE is 562.85x, while the forward PE is 37.29x. The enormous gap between trailing and forward PE implies the market expects earnings to grow roughly 15-fold over the next year, a heroic assumption that reflects either genuine operating leverage as acquisitions scale or simply the distortion from acquisition-related amortization and interest expense rolling off. The PS ratio of 20.53x and EV/Sales of 9.13x are more informative for a company at this stage, and both remain elevated relative to the broader Industrials/Aerospace & Defense sector, where mature primes typically trade at 2–4x sales.
Against industry averages, Karman trades at a steep premium on every metric: PS of 20.53x, PB of 25.30x, and EV/EBITDA of 85.42x are multiples typically reserved for high-growth software or early-stage disruptors, not defense hardware suppliers. The PEG ratio of 15.96 and price-to-book of 25.30x signal that the market has historically priced in extraordinary growth and returns, though the stock's 44.70% one-year decline has begun to compress these multiples from their post-IPO peaks. The premium is partially justified by Karman's 51% revenue growth and 42% gross margin, which exceed typical defense-sector growth of mid-single digits and gross margins of 20–30%, but the magnitude of the premium — particularly the 85x EV/EBITDA — leaves little room for execution error.
Historically, Karman's valuation has been extraordinarily volatile since its February 2025 IPO: the PS ratio ranged from 43.53x in Q4 2024 to a peak of 78.45x in Q3 2025 before compressing to the current 20.53x, while the PE ratio ranged from 244.99x in Q2 2025 to 562.85x today (distorted by the low earnings base). The current PS of 20.53x is less than half its Q3 2025 peak of 78.45x, suggesting the stock has undergone a significant de-rating — but even at 20.53x sales, it remains far above historical norms for the sector. The PB ratio of 25.30x is near the low end of its post-IPO range (12.66x to 26.15x), which could signal either a value opportunity if fundamentals hold or a warning that the market is repricing the company's acquisition-driven growth model downward.
PE
562.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 211x~439x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
85.4x
Enterprise Value Multiple
Investment Risk Disclosure
Karman faces significant financial and operational risks. The company's debt-to-equity ratio of 1.53 and total debt-to-capitalization of 68.12% indicate a heavily leveraged balance sheet, with interest coverage of just 1.70x. Despite reporting $7.79 million in net income for Q1 2026, operating cash flow was only $0.21 million and free cash flow was -$7.17 million, with TTM FCF at -$31.00 million. This cash burn, combined with $210.15 million spent on acquisitions in Q1 2026 alone, means the company remains dependent on external capital markets to fund its growth strategy. Additionally, net margin is thin at 5.15%, and ROE of 4.54% and ROA of 5.14% are below the cost of capital, highlighting subpar returns.
Market and competitive risks are also pronounced. The stock trades at a massive premium to peers, with a PS ratio of 20.53x and EV/EBITDA of 85.42x, versus typical aerospace & defense multiples of 2–4x sales. This valuation leaves little room for execution error and exposes the stock to severe multiple compression if growth decelerates. The recent short-seller report questioning the acquisition strategy has already triggered a 43.01% one-month decline, and the stock's beta is clearly well above 1, given its -70.17% max drawdown and -43.01% one-month move versus a -1.06% SPY change. Regulatory headwinds or changes in defense spending priorities could also impact demand, though current geopolitical tensions (Iran) provide a tailwind.
In a worst-case scenario, a continued deceleration in organic growth, failure to integrate acquisitions, or a negative response to the short-seller report could drive the stock below its 52-week low of $33.99. From the current price of $35.28, a drop to the 52-week low represents a -3.7% decline, but a breakdown below that level could open the door to price discovery with no historical support, potentially targeting the analyst low target of $78.00? No, that's upside. The realistic downside could be a further 20-30% decline if the company misses earnings or faces covenant issues, bringing the stock to the $25–$28 range. Investors could lose an additional 20-30% from current levels in this adverse scenario.
FAQ
The most severe risk is financial: Karman has negative TTM free cash flow of -$31.00 million, a debt-to-equity ratio of 1.53, and interest coverage of only 1.70x, which could lead to covenant breaches or dilutive financing. Second, competitive and execution risk: the short-seller report questions the acquisition strategy, and integrating $210.15 million of Q1 2026 acquisitions may prove challenging. Third, valuation risk: the stock trades at 20.53x sales and 85.42x EBITDA, so any growth disappointment could trigger severe multiple compression. Fourth, macro and geopolitical risk: defense spending is subject to political cycles, and the stock's high beta means it is vulnerable to market downturns.
Our 12-month forecast has three scenarios: a base case (50% probability) with a target range of $45–$65, assuming revenue growth moderates to 25–30% and free cash flow turns slightly positive; a bull case (25% probability) targeting $92.67–$135.00 if the company rebuts the short-seller report and demonstrates strong organic growth; and a bear case (25% probability) targeting $25–$33.99 if growth stalls or covenant issues arise. The most likely scenario is the base case, where the stock stabilizes but remains range-bound as the market awaits clearer evidence of organic growth and cash flow improvement. Key assumptions include gross margins holding above 40% and no major new negative news.
KRMN is significantly overvalued on traditional metrics, even after its 44.70% one-year decline. The trailing PE is 562.85x, PS is 20.53x, and EV/EBITDA is 85.42x, compared to aerospace & defense peers that typically trade at 2–4x sales and 10–15x EBITDA. The forward PE of 37.29x implies the market expects earnings to grow roughly 15-fold, a heroic assumption. While the PS ratio has compressed from a peak of 78.45x in Q3 2025 to 20.53x today, it remains far above historical norms. The market is pricing in extraordinary growth and successful acquisition integration, leaving little room for error.
KRMN is a high-risk, high-reward stock that may appeal to aggressive investors, but it is not a good buy for most portfolios at current levels. The stock trades at $35.28, just 3.8% above its 52-week low, and has fallen 43% in the past month due to a short-seller report and concerns about its acquisition strategy. While revenue grew 51% YoY in Q1 2026 and analysts have a strong_buy consensus with a $92.67 average target, the company burns cash (TTM FCF -$31.00 million) and carries high debt (debt-to-equity 1.53). The risk/reward is skewed to the downside until the company demonstrates positive free cash flow and addresses short-seller allegations.
KRMN is better suited for long-term, risk-tolerant investors rather than short-term traders, given its extreme volatility and early-stage growth profile. The stock has a beta well above 1 (implied by its -70.17% max drawdown and -43% one-month move), no dividend, and limited earnings visibility due to acquisition-related distortions. Short-term trading is highly risky given the falling-knife technical setup and potential for further downside. A minimum holding period of 2–3 years is advisable to allow the company to integrate acquisitions, improve cash flow, and potentially re-rate. Investors should size positions conservatively and be prepared for significant drawdowns.